All News
NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus
A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.
Read Article
Long-Term Hydroxychloroquine Retinopathy Risk
MedPage Today
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
Read Article
TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis
On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials.
UBER Rheumatology Ride (3.6.2026)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com
Read Article
Open-access Arthralgia Clinics
The early diagnosis in inflammatory arthritis (IA), particularly rheumatoid arthritis (RA), hinges on efficient referral and screening of arthralgia patients.
Treat-to-Target and Cardiovascular Benefits in Gout
A new user cohort study of 109 504 gout patients, achieving a serum urate level less than 6 mg/dL, was associated with a significantly lower risk of cardiovascular events.
Read Article
Hydroxychloroquine Lowers SLE and RA Hospitalizations
A population based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis
Poor sleep increases risk of #RA. English Longitudinal Study of Ageing. RA risk was signif. higher in those with moderate sleep quality (SQ) (HR 1.23) or poor SQ (HR 1.50), cmpared to good SQ. Partly mediated by depression https://t.co/kTbCUHeIGi https://t.co/6CD5tsKDdA
Links:
Dr. John Cush RheumNow ( View Tweet)
Muscular strength is a resilience marker relevant to function. A prospective cohort study of 5472 women (mean 79 yrs), showed that greater muscular strength (grip strength, chair stand time) was assoc w/ lower mortality (HR 0.85- 0.67) https://t.co/HEO4r2cdmS https://t.co/Ada3Bnrt0Z
Dr. John Cush RheumNow ( View Tweet)
Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/Het4GKaTmv
Dr. John Cush RheumNow ( View Tweet)
Open-access Arthralgia Clinics
The early diagnosis of IA, particularly RA, hinges on efficient referral and screening of arthralgia patients. Yet most rheumatology practices are ill-equipped or don't have EACs. This report describes the use of an OAC to manage primary care https://t.co/8ut6LkIUEX
Dr. John Cush RheumNow ( View Tweet)
Missed #RheumNowLive 2026?
The full meeting is now available On Demand.
✔ 2 days of clinical updates
✔ Expert faculty panels
✔ Speaker slides
✔ Pre-learn modules
Watch anytime for $250.
Learn from the meeting that kicks off the year in rheumatology.
🔗 Access here: https://t.co/jRvmbf87cs
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 8 articles, 2655 gout pts shows that ELEVATED neutrophil-to-lymphocyte ratio (NLR; SMD: 0.75; 95% CI: 0.48–1.03) and platelet-lymphocyte ratio (PLR; SMD: 0.52; 95% CI: 0.24–0.79) showed significant value in predicting acute gout attacks https://t.co/RaArPdoc2s https://t.co/Qi2WDSPlde
Dr. John Cush RheumNow ( View Tweet)
Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/G70POtJwhS
Dr. John Cush RheumNow ( View Tweet)
BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi? Find out in the RheumNow poster hall with data from the latest real-world study of long-term RA remission. Sponsored by AbbVieMedical Affairs + Health Impact. https://t.co/PPYVfz3tuC https://t.co/Boq8V3qqFp
Dr. John Cush RheumNow ( View Tweet)
Equivalent Healthcare Outcomes by Nurses and Physicians
With increasing demand for health services in an aging population, serving complex patients with comorbidities, and increasing healthcare costs, the question of whether nurses can substitute for physicians was addressed by https://t.co/nKsFn7pUgw
Dr. John Cush RheumNow ( View Tweet)
OA & Exercise? Metanalysis of 5 reviews (n=8631) & 28 trials (n=4360) show little or no proof that exercise benefits OA. Exercise has small, short-term effects vs placebo & no-treatment for knee OA pain. Moderate evidence of no effects in hip, & small effects in hand OA. https://t.co/ycLGNlP8Sf
Dr. John Cush RheumNow ( View Tweet)
The prevalence of Systemic lupus erythematosus (SLE) in Australia is 26,788 (16,294 certain, 10,494 uncertain cases). Betw 2010-2022 incidence was 77-127/100,000 (certain cases). About half had received SLE care in an outpatient setting. Australia is 1/13 the population of USA https://t.co/n1sbFNPRbn
Dr. John Cush RheumNow ( View Tweet)
3 Months of Romosozumab in Postmenopausal Osteoporosis
A report in The Lancet Diabetes & Endocrinology suggested that 3 months of romosozumab (ROMO) followed by denosumab is as effective at increasing hip bone mineral density (BMD) as the standard 12-month course. https://t.co/HPM7DdRFBM
Dr. John Cush RheumNow ( View Tweet)
Early vs Delayed Belimumab in Lupus
An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost-effectiveness and clinical utility of early BEL initiation in active lupus patients. https://t.co/7unHZhR6Dd
Dr. John Cush RheumNow ( View Tweet)
